9 22.00 (42.52, 0.86) 98 30.71 (46.97, 15.14) 99 five.42 (24.07, 10.37) 78 16.55 (31.31, 3.81) 99 17.85 (23.08, 13.02) 99 22.98 (47.31, 1.54) 97 7.29 (16.69, two.54) 95 15.97 (26.34, six.26) 99 11.09 (21.3, 0.09) 98 12.40 (29.01, six.63) 93 17.27 (45.84, 13.17) 88 1.84 (19.71, 19.57) 60 ten.60 (23.59, 4.53) 94 1.30 (15.15, 13.98) 59 six.23 (33.48, 21.98) 67 9.29 (six.19, 27.22) 9 0.56 (8.41, ten.64) 44 five.06 (29.83, 19.92) 65 ten.60 (0.05, 21.84) 2 1.85 (9.48, 12.93) 35 15.61 (10.48, 42.08) 11 6.93 (19.51, 33.04) 30 8.73 (23.05, four.56) 93 Comparator Placebo 0 MTX 14.71 (three.85, 33.43) five 0 aTNF 20.17 (12.33, 29.73) 1 5.42 (10.37, 24.07) 22 0 Tocilizumab 31.28 (18.69, 45.21) 1 16.55 (3.81, 31.31) 1 11.09 (0.09, 21.three) 2 0 aTNF MTX 32.53 (13.46, 52.09) 1 17.85 (13.02, 23.08) 1 12.40 (6.63, 29.01) 7 1.30 (13.98, 15.15) 41 0 Abatacept MTX 37.63 (6.71, 67.22) 1 22.98 (1.54, 47.31) three 17.27 (13.17, 45.84) 12 six.23 (21.98, 33.48) 33 5.06 (19.92, 29.83) 35 0 Anakinra MTX 22.00 (0.86, 42.52) 2 7.29 (2.54, 16.69) five 1.84 (19.57, 19.71) 40 9.29 (27.22, 6.19) 91 10.60 (21.84, 0.05) 98 15.61 (42.08, 10.48) 89 0 Tocilizumab MTX 30.71 (15.14, 46.97) 1 15.97 (6.26, 26.34) 1 10.60 (four.53, 23.59) 6 0.56 (10.64, 8.41) 56 1.85 (12.93, 9.48) 65 6.93 (33.04, 19.51) 70 8.73 (4.56, 23.05) 7P(improved) = Probability that treatment (in row) is showing higher efficacy than comparator (in column); CrI = credible interval; aTNF = Antitumor necrosis issue.Page 7 ofJansen et al. Overall health and Top quality of Life Outcomes 2014, 12:102 http://www.hqlo.com/content/12/1/Table 3 Remedy effects for all contrast with regards to patient worldwide assessment (PGA VAS) along with 95 credible interval and probability that remedy is superior than the comparatorIntervention Estimate Placebo 95 CrI P(much better) Estimate MTX 95 CrI P(much better) Estimate aTNF 95 CrI P(better) Estimate Tocilizumab 95 CrI P(much better) Estimate aTNF MTX 95 CrI P(superior) Estimate Abatacept MTX 95 CrI P(better) Estimate Anakinra MTX 95 CrI P(superior) Estimate Tocilizumab MTX 95 CrI P(much better) 14.32 (32, four.66) 95 17.35 (25.39, ten.63) 99 27.69 (40.53, 15.06) 99 33.49 (51.89, 14.01) 99 27.98 (50.46, three.21) 98 23.04 (42.eight, two.06) 98 29.43 (44.66, 13.49) 99 two.55750-62-4 structure 91 (21.31, 12.59) 66 13.22 (27.44, 0.76) 98 19.05 (24.21, 14.36) 99 13.62 (28.4, 1.97) 96 8.72 (17.84, 0.37) 97 15.06 (25.14, five.66) 99 10.29 (20.37, 0.80) 97 16.09 (32.53, two.65) 96 10.60 (31.58, 13.52) 84 5.83 (23.52, 15.01) 77 12.00 (24.98, 2.94) 96 five.76 (19.33, eight.91) 83 0.27 (19.62, 20.68) 51 4.46 (10.72, 21.41) 23 1.71 (ten.29, 7.84) 70 5.40 (ten.07, 22) 24 ten.34 (0.25, 20.94) 2 four.00 (six.Thieno[2,3-b]pyridin-5-amine Formula 97, 14.PMID:24190482 82) 19 four.86 (13.21, 22.16) 29 1.39 (20.05, 16.06) 57 6.30 (20.01, six.65) 88 Comparator Placebo 0 MTX 14.32 (4.66, 32) 5 0 aTNF 17.35 (10.63, 25.39) 1 two.91 (12.59, 21.31) 34 0 Tocilizumab 27.69 (15.06, 40.53) 1 13.22 (0.76, 27.44) two ten.29 (0.8, 20.37) 3 0 aTNF MTX 33.49 (14.01, 51.89) 1 19.05 (14.36, 24.21) 1 16.09 (2.65, 32.53) four five.76 (8.91, 19.33) 17 0 Abatacept MTX 27.98 (three.21, 50.46) 2 13.62 (1.97, 28.four) four ten.60 (13.52, 31.58) 16 0.27 (20.68, 19.62) 49 five.40 (22, ten.07) 76 0 Anakinra MTX 23.04 (two.06, 42.eight) 2 eight.72 (0.37, 17.84) 3 five.83 (15.01, 23.52) 23 4.46 (21.41, 10.72) 77 ten.34 (20.94, 0.25) 98 four.86 (22.16, 13.21) 71 0 Tocilizumab MTX 29.43 (13.49, 44.66) 1 15.06 (5.66, 25.14) 1 12.00 (two.94, 24.98) four 1.71 (7.84, 10.29) 30 4.00 (14.82, six.97) 81 1.39 (16.06, 20.05) 43 6.30 (6.65, 20.01).